Objective: This study aims to demonstrate real-life effectiveness of dupilumab treatment in moderate-to-severe atopic dermatitis patients.
Methods: The 14 patients diagnosed with moderate-to-severe atopic dermatitis were included in this study. All of the patients started dupilumab treatment in our faculty between October 2019 and October 2020. The patients were evaluated at the beginning of the treatment and after 12 weeks of treatments. The baseline scoring atopic dermatitis (SCORAD) scores, the total immunoglobulin E (IgE) levels, and the visual analog scale (VAS) of 0-10 points for itch intensity compared with the post-treatment scores.
Results: The SCORAD scores, the serum total IgE levels, and the VAS itch scores of the patients receiving dupilumab treatment dropped significantly following 12 weeks of dupilumab treatment. No significant correlation was demonstrated between the initial SCORAD scores and the serum total IgE values. Besides, no correlation was shown to exist in the reduction of the SCORAD and the serum total IgE values after dupilumab treatment.
Conclusion: Dupilumab treatment showed significant improvement in disease severity with remarkable reduction in serum total IgE levels.
Keywords: Atopic dermatitis; dupilumab; scoring atopic dermatitis.
Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.